Jared Holz on Novo Nordisk: Why Not to Buy the Dip Yet

Novo Nordisk's Guidance Cut and Stock Performance

• 📉 Novo Nordisk experienced its worst day since 1987, with a double-digit drop following a significant cut to its full-year guidance.
• ⚠️ The company now anticipates weaker growth for its GLP-1 drugs, including Wegovy, in the second half of the year.
• 💼 The company also announced the appointment of its new CEO, Mike Dotstar, effective August 7th.

Market Expectations and Share Growth

• 📊 Analysts are expected to scrutinize both near-term and longer-term obesity market expectations, which have become excessively high.
• 📈 Street models for the total market size have rapidly escalated from $50 billion to over $150 billion, suggesting expectations may have risen too quickly.
• ❓ The breakdown of market share in the second quarter remains uncertain.

Factors Influencing Drug Demand

• 💊 Cheaper alternatives to these drugs are emerging, and both Novo Nordisk and Eli Lilly have reduced prices over time.
• 💡 The speaker views the GLP-1 drugs as largely consumer products rather than purely therapeutic ones, with patients likely cycling on and off the medication.
• 🧩 Modeling demand for a consumer product is significantly more complex than for a therapeutic drug.

Investment Outlook for Novo Nordisk

• ⏳ While the stock is down significantly, today is not the day to buy the dip; it's advisable to wait for Eli Lilly's results next week.
• 📈 Long-term, the stock is considered okay, especially with a new management team.
• ⚠️ The previous management is criticized for standing still when things were going well, failing to adequately mitigate current risks.
• 🏃 It's better to miss the initial few percent of a rebound than to buy too early in a volatile situation.